Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/2231
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | FAIAO-FLORES, Femanda | - |
dc.contributor.author | COELHO, Paulo Rogerio Pinto | - |
dc.contributor.author | ARRUDA-NETO, Joao Dias Toledo | - |
dc.contributor.author | MARIA-ENGLER, Silvya Stuchi | - |
dc.contributor.author | MARIA, Durvanei Augusto | - |
dc.date.accessioned | 2013-09-23T16:44:56Z | - |
dc.date.available | 2013-09-23T16:44:56Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | TOXICOLOGY IN VITRO, v.27, n.4, Special Issue, p.1196-1204, 2013 | - |
dc.identifier.issn | 0887-2333 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/2231 | - |
dc.description.abstract | Boron Neutron Capture Therapy (BNCT) involves the selective accumulation of boron carriers in tumor tissue followed by irradiation with a thermal or epithermal neutron beam. This therapy is therefore a cellular irradiation suited to treat tumors that have infiltrated into healthy tissues. BNCT has been used clinically to treat patients with cutaneous melanomas which have a high mortality. Human normal melanocytes and melanoma cells were treated with BNCT at different boronophenylalanine concentrations for signaling pathways analysis. BNCT induced few morphological alterations in normal melanocytes, with a negligible increase in free radical production. Melanoma cells treated with BNCT showed significant extracellular matrix (ECM) changes and a significant cyclin D1 decrease, suggesting cell death by necrosis and apoptosis and cell cycle arrest, respectively. BNCT also induced a significant increase in cleaved caspase-3 and a decrease in the mitochondrial electrical potential with selectivity for melanoma cells. Normal melanocytes had no significant differences due to BNCT treatment, confirming the data from the literature regarding the selectivity of BNCT. The results from this study suggest that some signaling pathways are involved in human melanoma treatment by BNCT, such as cell cycle arrest, ECM changes and intrinsic apoptosis. | - |
dc.language.iso | eng | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.relation.ispartof | Toxicology in Vitro | - |
dc.rights | restrictedAccess | - |
dc.subject | Boron Neutron Capture Therapy (BNCT) | - |
dc.subject | Boronophenylalanine (BPA) | - |
dc.subject | Melanoma | - |
dc.subject | Normal melanocytes | - |
dc.subject | Cell cycle arrest | - |
dc.subject | Apoptosis | - |
dc.subject.other | cutaneous melanoma | - |
dc.subject.other | skin melanoma | - |
dc.subject.other | assay | - |
dc.subject.other | bnct | - |
dc.subject.other | toxicity | - |
dc.subject.other | phosphatidylserine | - |
dc.subject.other | proliferation | - |
dc.subject.other | expression | - |
dc.subject.other | microscopy | - |
dc.subject.other | carcinoma | - |
dc.title | Cell cycle arrest, extracellular matrix changes and intrinsic apoptosis in human melanoma cells are induced by Boron Neutron Capture Therapy | - |
dc.type | article | - |
dc.rights.holder | Copyright PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.identifier.doi | 10.1016/j.tiv.2013.02.006 | - |
dc.identifier.pmid | 23462526 | - |
dc.subject.wos | Toxicology | - |
dc.type.category | original article | - |
dc.type.version | publishedVersion | - |
hcfmusp.author.external | COELHO, Paulo Rogerio Pinto:Inst Nucl & Energy Res, Sao Paulo, Brazil | - |
hcfmusp.author.external | ARRUDA-NETO, Joao Dias Toledo:Univ Sao Paulo, Inst Phys, Sao Paulo, Brazil; Unitalo Univ Ctr, Sao Paulo, Brazil | - |
hcfmusp.author.external | MARIA-ENGLER, Silvya Stuchi:Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Sao Paulo, Brazil | - |
hcfmusp.author.external | MARIA, Durvanei Augusto:Butantan Inst, Biochem & Biophys Lab, Sao Paulo, Brazil | - |
hcfmusp.description.beginpage | 1196 | - |
hcfmusp.description.endpage | 1204 | - |
hcfmusp.description.issue | 4 | - |
hcfmusp.description.issue | Special Issue | - |
hcfmusp.description.volume | 27 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | 2-s2.0-84875131065 | - |
hcfmusp.origem.id | WOS:000318838000002 | - |
hcfmusp.publisher.city | OXFORD | - |
hcfmusp.publisher.country | ENGLAND | - |
hcfmusp.relation.reference | Baker GL, 2005, CELL CYCLE, V4, P330 | - |
hcfmusp.relation.reference | Barth RF, 2004, INT J RADIAT ONCOL, V58, P267, DOI 10.1016/S0360-3016(03)01613-4 | - |
hcfmusp.relation.reference | Barth RF, 2005, CLIN CANCER RES, V11, P3987, DOI 10.1158/1078-0432.CCR-05-0035 | - |
hcfmusp.relation.reference | Chakrabartil A., 2012, NANOTECHNOL LIFE SCI, V16, P403 | - |
hcfmusp.relation.reference | Chen M, 2009, MOL CANCER RES, V7, P703, DOI 10.1158/1541-7786.MCR-08-0263 | - |
hcfmusp.relation.reference | Chen Y, 2001, CANCER RES, V61, P6437 | - |
hcfmusp.relation.reference | CODERRE JA, 1994, INT J RADIAT ONCOL, V30, P643 | - |
hcfmusp.relation.reference | Coelho PRP, 2002, RESEARCH AND DEVELOPMENT IN NEUTRON CAPTURE THERAPY, P197 | - |
hcfmusp.relation.reference | Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558 | - |
hcfmusp.relation.reference | Esposito J, 2008, NUCL INSTRUM METH B, V266, P2587, DOI 10.1016/j.nimb.2008.03.239 | - |
hcfmusp.relation.reference | FADOK VA, 1992, J IMMUNOL, V148, P2207 | - |
hcfmusp.relation.reference | Faiao-Flores F, 2011, APPL RADIAT ISOTOPES, V69, P1748, DOI 10.1016/j.apradiso.2011.05.017 | - |
hcfmusp.relation.reference | Faiao-Flores F, 2011, APPL RADIAT ISOTOPES, V69, P1741, DOI 10.1016/j.apradiso.2011.03.005 | - |
hcfmusp.relation.reference | Faiao-Flores F, 2012, RADIAT ENVIRON BIOPH, V51, P319, DOI 10.1007/s00411-012-0416-y | - |
hcfmusp.relation.reference | Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686 | - |
hcfmusp.relation.reference | Fujita Y, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-63 | - |
hcfmusp.relation.reference | Fuller KM, 2003, CURR OPIN BIOTECH, V14, P35, DOI 10.1016/S0958-1669(02)00008-3 | - |
hcfmusp.relation.reference | Gnewuch CT, 2002, CELL MOL LIFE SCI, V59, P959, DOI 10.1007/s00018-002-8483-x | - |
hcfmusp.relation.reference | Gonzalez SJ, 2004, APPL RADIAT ISOTOPES, V61, P1101, DOI 10.1016/j.apradiso.2004.05.060 | - |
hcfmusp.relation.reference | Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147 | - |
hcfmusp.relation.reference | Hughes AM, 2011, ORAL ONCOL, V47, P1017, DOI 10.1016/j.oraloncology.2011.07.014 | - |
hcfmusp.relation.reference | JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772 | - |
hcfmusp.relation.reference | Kamida A, 2008, INT J RADIAT BIOL, V84, P191, DOI 10.1080/09553000801902125 | - |
hcfmusp.relation.reference | Kennady PK, 2004, CYTOM PART A, V62A, P97, DOI 10.1002/cyto.a.20091 | - |
hcfmusp.relation.reference | Koren R, 2001, ACTA HISTOCHEM, V103, P151, DOI 10.1078/0065-1281-00587 | - |
hcfmusp.relation.reference | Li W, 2006, PATHOLOGY, V38, P287, DOI 10.1080/00313020600817951 | - |
hcfmusp.relation.reference | Makino H, 2000, Kidney Int Suppl, V77, pS67 | - |
hcfmusp.relation.reference | Menendez PR, 2009, APPL RADIAT ISOTOPES, V67, pS50, DOI 10.1016/j.apradiso.2009.03.020 | - |
hcfmusp.relation.reference | Menichetti L, 2009, APPL RADIAT ISOTOPES, V67, pS336, DOI 10.1016/j.apradiso.2009.03.058 | - |
hcfmusp.relation.reference | Mishima Y, 1996, CANCER NEUTRON CAPTURE THERAPY, P1 | - |
hcfmusp.relation.reference | MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4 | - |
hcfmusp.relation.reference | Nakamura H., 2011, ORG BIOMOL CHEM, V10, P1374 | - |
hcfmusp.relation.reference | OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3 | - |
hcfmusp.relation.reference | Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412 | - |
hcfmusp.relation.reference | Pawlik TM, 2003, CRIT REV ONCOL HEMAT, V45, P245, DOI 10.1016/S1040-8428(02)00080-X | - |
hcfmusp.relation.reference | PICKERING JG, 1991, AM J PATHOL, V138, P1225 | - |
hcfmusp.relation.reference | Sauter ER, 2002, CANCER RES, V62, P3200 | - |
hcfmusp.relation.reference | Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454 | - |
hcfmusp.relation.reference | Joensuu Heikki, 2011, Duodecim, V127, P1697 | - |
hcfmusp.relation.reference | Toppino A, 2013, CHEM-EUR J, V19, P720, DOI 10.1002/chem.201201634 | - |
hcfmusp.relation.reference | van Kempen LCLT, 2008, INT J CANCER, V122, P1019, DOI 10.1002/ijc.23147 | - |
hcfmusp.relation.reference | VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I | - |
hcfmusp.relation.reference | Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353 | - |
hcfmusp.relation.reference | Wunrau C, 2009, ARTHRITIS RHEUM, V60, P2606, DOI 10.1002/art.24782 | - |
dc.description.index | MEDLINE | - |
hcfmusp.citation.scopus | 10 | - |
hcfmusp.scopus.lastupdate | 2022-05-06 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/Outros Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_FAIAO-FLORES_Cell_cycle_arrest_extracellular_matrix_changes_and_intrinsic_2013.PDF Restricted Access | publishedVersion (English) | 1.1 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.